Adam S Levy1, Mark Krailo2, Susan Chi3, Doojduen Villaluna4, Linda Springer4, Chris Williams-Hughes2, Maryam Fouladi5, Amar Gajjar6. 1. Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, New York, USA. 2. Department of Preventive Medicine, University of Southern California, Los Angeles, California, USA. 3. Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA. 4. Children's Oncology Group, Monrovia, California, USA. 5. Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. 6. Saint Jude Children's Research Hospital, Memphis, Tennessee, USA.
Abstract
BACKGROUND: Approximately 30% of children with medulloblastoma (MB) experience recurrence, which is usually incurable. This study compared the overall survival (OS) of patients receiving temozolomide (TMZ) and irinotecan with that of patients receiving TMZ, irinotecan, and bevacizumab for recurrent MB/central nervous system (CNS) primitive neuroectodermal tumor (PNET). METHODS: Patients with relapsed/refractory MB or CNS PNET were randomly assigned to receive TMZ (150 mg/m2 /day PO on days 1-5) and irinotecan (50 mg/m2 /day IV on days 1-5) with or without bevacizumab (10 mg/kg IV on days 1 and 15). RESULTS: One hundred five patients were eligible and treated on study. Median OS was 13 months in the standard arm and 19 months with the addition of bevacizumab; median event-free survival (EFS) was 6 months in the standard arm and 9 months with the addition of bevacizumab. The hazard ratio for death from the stratified relative-risk regression model is 0.63. Overall, 23 patients completed 12 courses of planned protocol therapy, 23% (12/52) in the experimental arm with bevacizumab versus 21% (11/53) in the standard arm. Toxicity profiles were comparable in both treatment arms. The estimate of the incidence of feasibility events associated with the bevacizumab arm is three of 52 (5.8%) (95% CI 1.2-16%). Events included myelosuppression, electrolyte abnormalities, diarrhea, and elevated transaminases. One intracranial hemorrhage event was observed in each arm. CONCLUSION: The addition of bevacizumab to TMZ/irinotecan significantly reduced the risk of death in children with recurrent MB. The combination was relatively well tolerated in this heavily pretreated cohort. The three-drug regimen demonstrated a sufficient risk reduction to warrant further investigation.
BACKGROUND: Approximately 30% of children with medulloblastoma (MB) experience recurrence, which is usually incurable. This study compared the overall survival (OS) of patients receiving temozolomide (TMZ) and irinotecan with that of patients receiving TMZ, irinotecan, and bevacizumab for recurrent MB/central nervous system (CNS) primitive neuroectodermal tumor (PNET). METHODS: Patients with relapsed/refractory MB or CNS PNET were randomly assigned to receive TMZ (150 mg/m2 /day PO on days 1-5) and irinotecan (50 mg/m2 /day IV on days 1-5) with or without bevacizumab (10 mg/kg IV on days 1 and 15). RESULTS: One hundred five patients were eligible and treated on study. Median OS was 13 months in the standard arm and 19 months with the addition of bevacizumab; median event-free survival (EFS) was 6 months in the standard arm and 9 months with the addition of bevacizumab. The hazard ratio for death from the stratified relative-risk regression model is 0.63. Overall, 23 patients completed 12 courses of planned protocol therapy, 23% (12/52) in the experimental arm with bevacizumab versus 21% (11/53) in the standard arm. Toxicity profiles were comparable in both treatment arms. The estimate of the incidence of feasibility events associated with the bevacizumab arm is three of 52 (5.8%) (95% CI 1.2-16%). Events included myelosuppression, electrolyte abnormalities, diarrhea, and elevated transaminases. One intracranial hemorrhage event was observed in each arm. CONCLUSION: The addition of bevacizumab to TMZ/irinotecan significantly reduced the risk of death in children with recurrent MB. The combination was relatively well tolerated in this heavily pretreated cohort. The three-drug regimen demonstrated a sufficient risk reduction to warrant further investigation.
Authors: Christopher D Turner; Sridharan Gururangan; James Eastwood; Krystal Bottom; Melody Watral; Rodney Beason; Roger E McLendon; Allan H Friedman; Sandra Tourt-Uhlig; Langdon L Miller; Henry S Friedman Journal: Neuro Oncol Date: 2002-04 Impact factor: 12.300
Authors: Anna M Butturini; Mary Jacob; Jennifer Aguajo; Noam A Vander-Walde; Judy Villablanca; Rima Jubran; Anat Erdreich-Epstein; Araz Marachelian; Girish Dhall; Jonathan L Finlay Journal: Cancer Date: 2009-07-01 Impact factor: 6.860
Authors: Phillip A Bonney; Joshua A Santucci; Adrian J Maurer; Michael E Sughrue; Rene Y McNall-Knapp; James D Battiste Journal: J Clin Neurosci Date: 2016-01-14 Impact factor: 1.961
Authors: Francisco Bautista; Victoria Fioravantti; Teresa de Rojas; Fernando Carceller; Luis Madero; Alvaro Lassaletta; Lucas Moreno Journal: Cancer Med Date: 2017-10-04 Impact factor: 4.452
Authors: Rebecca M Hill; Sabine L A Plasschaert; Beate Timmermann; Christelle Dufour; Kristian Aquilina; Shivaram Avula; Laura Donovan; Maarten Lequin; Torsten Pietsch; Ulrich Thomale; Stephan Tippelt; Pieter Wesseling; Stefan Rutkowski; Steven C Clifford; Stefan M Pfister; Simon Bailey; Gudrun Fleischhack Journal: Cancers (Basel) Date: 2021-12-28 Impact factor: 6.575
Authors: Christine Gaab; Jonas E Adolph; Stephan Tippelt; Ruth Mikasch; Denise Obrecht; Martin Mynarek; Stefan Rutkowski; Stefan M Pfister; Till Milde; Olaf Witt; Brigitte Bison; Monika Warmuth-Metz; Rolf-Dieter Kortmann; Stefan Dietzsch; Torsten Pietsch; Beate Timmermann; Ronald Sträter; Udo Bode; Andreas Faldum; Robert Kwiecien; Gudrun Fleischhack Journal: Cancers (Basel) Date: 2022-01-18 Impact factor: 6.639
Authors: Simon Bailey; Nicolas André; Lorenza Gandola; Maura Massimino; Stefan Rutkowski; Steven C Clifford Journal: Cancers (Basel) Date: 2022-01-13 Impact factor: 6.575